Isolation and molecular characterization of a human T-cell lymphotropic virus type II (HTLV-II), subtype B, from a healthy Pygmy living in a remote area of Cameroon: an ancient origin for HTLV-II in Africa

A Gessain, P Mauclère, A Froment, M Biglione, J Y Le Hesran, F Tekaia, J Millan, G de Thé, A Gessain, P Mauclère, A Froment, M Biglione, J Y Le Hesran, F Tekaia, J Millan, G de Thé

Abstract

We report characterization of a human T-cell lymphotropic virus type II (HTLV-II) isolated from an interleukin 2-dependent CD8 T-cell line derived from peripheral blood mononuclear cells of a healthy, HTLV-II-seropositive female Bakola Pygmy, aged 59, living in a remote equatorial forest area in south Cameroon. This HTLLV-II isolate, designated PYGCAM-1, reacted in an indirect immunofluorescence assay with HTLV-II and HTLV-I polyclonal antibodies and with an HTLV-I/II gp46 monoclonal antibody but not with HTLV-I gag p19 or p24 monoclonal antibodies. The cell line produced HTLV-I/II p24 core antigen and retroviral particles. The entire env gene (1462 bp) and most of the long terminal repeat (715 bp) of the PYGCAM-1 provirus were amplified by the polymerase chain reaction using HTLV-II-specific primers. Comparison with the long terminal repeat and envelope sequences of prototype HTLV-II strains indicated that PYGCAM-1 belongs to the subtype B group, as it has only 0.5-2% nucleotide divergence from HTLV-II B strains. The finding of antibodies to HTLV-II in sera taken from the father of the woman in 1984 and from three unrelated members of the same population strongly suggests that PYGCAM-1 is a genuine HTLV-II that has been present in this isolated population for a long time. The low genetic divergence of this African isolate from American isolates raises questions about the genetic variability over time and the origin and dissemination of HTLV-II, hitherto considered to be predominantly a New World virus.

References

    1. Adv Virus Res. 1994;43:147-86
    1. J Virol. 1994 Dec;68(12):8392-5
    1. Virology. 1994 Jul;202(1):379-89
    1. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
    1. Lancet. 1982 Sep 18;2(8299):658
    1. Science. 1982 Nov 5;218(4572):571-3
    1. Proc Natl Acad Sci U S A. 1985 May;82(10):3101-5
    1. Mol Biol Evol. 1987 Jul;4(4):406-25
    1. Blood. 1990 Jan 15;75(2):428-33
    1. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8840-4
    1. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1446-50
    1. AIDS. 1991 Jun;5(6):771-2
    1. Int J Cancer. 1991 Sep 30;49(3):373-6
    1. J Virol. 1992 Apr;66(4):2288-95
    1. J Virol. 1992 Apr;66(4):2456-63
    1. Blood. 1992 May 15;79(10):2789-96
    1. Comput Appl Biosci. 1992 Apr;8(2):189-91
    1. J Infect Dis. 1992 Jul;166(1):100-7
    1. Nature. 1992 Sep 17;359(6392):201
    1. J Virol. 1993 Mar;67(3):1175-84
    1. J Acquir Immune Defic Syndr. 1993 Mar;6(3):324-5
    1. J Acquir Immune Defic Syndr. 1993 Jun;6(6):631-3
    1. J Virol. 1993 Aug;67(8):4659-64
    1. J Infect Dis. 1993 Sep;168(3):737-40
    1. Virology. 1993 Sep;196(1):57-69
    1. AIDS Res Hum Retroviruses. 1993 Aug;9(8):707
    1. AIDS Res Hum Retroviruses. 1993 Aug;9(8):709-13
    1. Virology. 1993 Dec;197(2):576-84
    1. J Acquir Immune Defic Syndr. 1993 Dec;6(12):1373-4
    1. AIDS. 1993 Oct;7(10):1394-5
    1. AIDS Res Hum Retroviruses. 1993 Oct;9(10):1039-42
    1. J Virol. 1994 Feb;68(2):1149-57
    1. Jpn J Cancer Res. 1993 Dec;84(12):1215-8
    1. J Virol. 1994 Apr;68(4):2693-707
    1. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2848-52
    1. Leukemia. 1994 Apr;8 Suppl 1:S60-4
    1. Lancet. 1994 Jul 23;344(8917):265-6
    1. AIDS Res Hum Retroviruses. 1994 Jun;10(6):753-5
    1. Virology. 1994 Jul;202(1):212-23

Source: PubMed

3
订阅